

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Dan P. Felsenfeld et al.

Application No.: 10/561,015

Confirmation No.: 9430

Filed: February 17, 2006

Art Unit: N/A

For: METHODS AND AGENTS FOR TREATING  
AXONAL DAMAGE, INHIBITION OF  
NEUROTRANSMITTER RELEASE AND  
PAIN TRANSMISSION, AND BLOCKING  
CALCIUM INFLUX IN NEURONS

---

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:  
(Check one of the boxes A-D)

- ☐ A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above identified national application
- ☒ B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- ☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- ☐ i. Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))
- ☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- ☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- ☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 CFR 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was

(check one of the boxes "a" and "b" below:)

- ☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- ☐ (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

- ☐ A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.
- ☐ B. Document(s) \_\_\_\_\_ is (are) deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- ☐ C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

<<INSERT SERIAL NO. & FILING DATE>>

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

- ☐ 3. Cite No(s). \_\_\_\_\_ are not in the English language.  
In accordance with 1.98(c), Applicant states:

- ☐ An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- ☐ The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is set forth as follows: [Insert concise explanation of relevance]
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.
- ☐ A concise explanation of document(s) \_\_\_\_\_ can be found on the attached sheet.

- ☒ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
- ☐ 5. Other information being provided for the examiner's consideration follows:

[A/An \_\_\_\_\_ Search Report, dated \_\_\_\_\_, which issued during the prosecution of \_\_\_\_\_ Application No. \_\_\_\_\_ which corresponds to the present application.]

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 16, 2006

Respectfully submitted,

By MARIE COLLAZO 4485

Howard M. Frankfort

Registration No.: 32,613

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Substitute for form 1449PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/561,015-Conf. #9430
Filing Date	February 17, 2006
First Named Inventor	Dan P. Felsenfeld
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	02420/100M761-US1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1 <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP §601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Davis and Bennett J Biol Chem 1994;269:27163-27166	
	CB	De Angelis et al., J Biol Chem 2001;276:32738-32742	
	CC	Dalcour, Ah, and Tsien RW. 1993. Science Feb. 12, 259 (5097): 980-84	
	CD	Derossi d. et al., Trends Cell Biol 1998;8:84-87	
	CE	Dickson et al. J Cell Biol 2002;157:1105-1112	
	CF	Dunlap K, et al. J Physiol. 1981, 317:519-535	
	CG	Gil OD et al., J. Cell. Biol 2003, Aug. 18, 162 (4) 719-30	
	CH	Herlitz S, et al. Nature. 1996 Mar 21;380(6571) 259-62	
	CI	Hille B. Trends Neurosci. 1994 Dec; 17(12):531-6	
	CJ	Hortsch et al. Cell Adhes Commun 1998;5:61-73	
	CK	Hortsch M. et al., Molecular and Cellular Neuroscience 15, 1-10 (2000)	
	CL	Ikedo SR. Nature. 1996 Mar 21;380(6571): 255-8	
	CM	Jenkins SM and Bennett V. (2001). J. Cell Biol. 155:739-45	
	CN	Kamiguchi and Yoshihara J. Neurosci 2001;21:9194-9203	
	CO	Kamiguchi and Lemmon J Neurosci 1998;18:3749-3756	
	CP	Kizhatil et al. J Neurosci 2002;22:7945-7958	
	CQ	Mattson MP, et al., Neuromolecular Med. 2003;3(2): 65-94	
	CR	Maximov A., Bezprozvanny I. J Neurosci. 22:6939-52	
	CS	Miura et al. FEBS Lett 1991;289:91-95	
	CT	Mody I, et al., Trends Pharmacol Sci. 1995; Oct; 16(10): 356-9	
	CU	Needham et al. J Neurosci 2001;21:1490-1500	
	CV	Schaefer et al. J Cell Biol 2002;157:1223-1232	
	CW	Tuvia et al. J Cell Biol 1999;147:995-1007	
	CX	Zheng Z. et al., Curr Mol Med. 2003 Jun;3(4):361-72	
	CY	Zisch et al. J Neurosci Res 1997;47:655-65	

W-1024  
201-100

00664852.doc

Date  
Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/561,015-Conf. #9430
				Filing Date	February 17, 2006
				First Named Inventor	Dan P. Felsenfeld
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	02420/100M761-US1

CZ	Kamiguchi et al. J Neurosci 1996;18:5311-21	
----	---	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached

(W)024 200100		Date Considered	
------------------	--	--------------------	--

006046/2 doc